SOLICITATION NOTICE
B -- Gene Network Analysis of PTPN14 in mouse skin, lung and mammary tissue
- Notice Date
- 8/7/2013
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(HG)-2013-237-DLM
- Archive Date
- 8/29/2013
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- i. This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. ii. The solicitation number is NHLBI-CSB-(HG)-2013-237-DLM and the solicitation is being posted as a request for proposal (RFP). Offerors shall submit their proposals no later than 7:30 a.m. Eastern Standard Time (EST) on August 14, 2013. iii. A statement that the solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-69, August 1, 2013. iv. The associated North American Industry Classification System (NAICS) code for this is 541712, Research and Development in the Physical, Engineering, and Life Sciences (except biotechnology) and small business size standard is 500. A. Background : The National Institute of Health (NIH) is the nation's leading medical research agency and the primary Federal agency conducting, supporting and making medical discoveries that improve people's health and save lives. The National Institutes of Health Undiagnosed Disease Program (UDP) is a trans-National Institute of Health (NIH) initiative that focuses on the most puzzling medical cases referred to the NIH Clinical Center in Bethesda, MD. It was organized by the National Human Genome Research Institute (NHGRI), the NIH Office of Rare Diseases Research (ORDR) and the NIH Clinical Center. Many medical specialties from other NIH research centers and institutes contribute the expertise needed to conduct the program, including endocrinology, immunology, oncology, dermatology, dentistry, cardiology and genetics, among the dozens of participating senior attending physicians. A longstanding medical condition that eludes diagnosis by a referring physician can be considered undiagnosed and may be of interest to this clinical research program. The DIR-NHGRI- Undiagnosed Diseases program (UDP) protocol 76-HG-0238, Clinical Trial Number: NCT00369421 are connected to this testing, which began in 2008 as a vehicle for admitting patients with broader range of inborn errors of metabolism. Under this observational protocol study, the Researchers in the Protocol study have identified patients exhibiting pathogenic variants in the PTPN14 gene that are linked to a short stature phenotype. B. Purpose and Objectives : The purpose of this acquisition is to determine if the mutation of PTPN14 identified in the NIH UDP patients 809 and 810 is the likely cause of their short stature. The contractor shall determine if the identified mutation alters expression or subcellular localization of the PTPN14 protein and if there are alterations of PTPN14-regulated gene expression in patient peripheral blood or cultured skin fibroblast. These will be done to access the contribution of mutation of PTPN14 to the disease phenotype of UDP patients 809 and 810. Requirements of this acquisition are as follows: • The Contractor shall perform Gene Expression Network Analysis of PTPN14 in mouse skin, lung and mammary tissue. • The Contractor shall establish cultures of patient (n=2), parent (n=2) and aged and gender matched control human fibroblasts (n=6). • The Contractor shall receive patient, parent and control human bloods (n=10) and extract RNA from patient, parent and control human bloods. • The Contractor shall perform RT-PCR analysis of PTPN14 transcripts in RNA from patient, parent and control human blood and fibroblasts. • The Contractor shall perform qRT-PCR (TAQMAN) analysis of ITPR3 and PTPN13 transcripts in RNA from patient, parent and control human blood and fibroblasts • The Contractor shall generate of PTPN14-WT and PTPN14 p.Glu189Gly gene expression constructs. • The Contractor shall generate lentiviral shPTPN14 expression constructs. • The Contractor shall test expression of tagged PTPN14-WT and tagged-PTPN14 p.Glu189Gly and lentiviral shPTPN14 constructs in MCF10A cells for effects on PTPN14, PTPN13 and ITPR3 expression by qRT-PCR. • The Contractor shall supply real-time free and full sharing of all data with the UDP. The Contractor shall supply electronic copies of all reports appropriate for deposition in the UDP process management system. C. Scope of Work Specifically the contractor shall : • Determine if the mutation of PTPN14 identified in the NIH UDP patients 809 and 810 is a likely cause of their short stature • Evaluate tissues from the identified patient for evidence of dysfunction of the mutant PTPN14 protein by accessing gene expression networks regulated by this protein. • Communicate with UDP about collected data and results. Upon conclusion of the analysis, UDP will make recommendations for future studies. D. Other considerations : 1. Bioinformatics Gene Expression Network Analysis of PTPN14 in mouse skin, lung and mammary tissue; 2. Attempt culture of patient (n=2), parent (n=2) and aged and gender matched control human fibroblasts (n=6); • Immortalization of patient, parent and control human fibroblasts • Extraction of RNA from patient, parent and control human fibroblasts • Cryopreservation of patient, parent and control human fibroblasts 3. Receive patient, parent and control human bloods (n=10) and extract RNA from patient, parent and control human bloods; 4. RT-PCR analysis of PTPN14 transcripts in RNA from patient, parent and control human blood and fibroblasts; 5. qRT-PCR (TAQMAN) analysis of ITPR3 and PTPN13 transcripts in RNA from patient, parent and control human blood and fibroblasts; 6. Generation of PTPN14-WT and PTPN14 p.Glu189Gly gene expression constructs; and 7. Generation of lentiviral shPTPN14 expression construct. E. Anticipated Period of Performance: Twelve (12) months from the date of award. v. NIH/UDP is located at 9 Memorial Drive, Bethesda, Maryland 20892. vi. The FAR Provision 52.212-1, Instructions to Offerors -- Commercial, applies to this acquisition and is hereby incorporated by reference. All Federal Acquisition Regulations (FAR) clauses may be viewed at http://acquisition.gov/comp/far/index.html. vii. EVALUATION OF PROPOSALS The Government will evaluate proposals that are determined technically acceptable in accordance with the Technical Evaluation factors. The Government intends to award a single contract from this solicitation. The Government reserves the right not to award a contract. Evaluation of Proposals: The Government reserves the right to make an award without discussions based solely upon initial proposals. EVALUATION FACTORS: 1. Ability to perform Gene Expression Network Analysis of PTPN14 in mouse skin, lung and mammary tissue. 2. Ability to perform RT-PCR analysis of PTPN14 transcripts in RNA from patient, parent and control human blood and fibroblasts. 3. Ability to perform qRT-PCR (TAQMAN) analysis of ITPR3 and PTPN13 transcripts in RNA from patient, parent and control human blood and fibroblasts 4. Ability to generate lentiviral shPTPN14 expression constructs. 5. Ability to test expression of tagged PTPN14-WT and tagged-PTPN14 p.Glu189Gly and lentiviral shPTPN14 constructs in MCF10A cells for effects on PTPN14, PTPN13 and ITPR3 expression by qRT-PCR. 6. Must have over 10-years' experience in conducting mutation analyses research. A. Price (This will be Firm-Fixed Price): An evaluation of the offeror's price proposal will be made to determine if proposed prices are realistic for the work to be performed, reflect a clear understanding of the requirements, and are consistent with the technical proposal. Reasonableness determinations will be made by determining if competition exists, by comparing proposed prices with established commercial or GSA price schedules (if applicable), and/or by comparing proposed prices with the Independent Government Cost Estimate (IGCE). viii. In accordance with FAR Clause 52.212-3, Offeror Representations and Certifications - Commercial Items, offerors must complete annual representations and certifications on-line at https://www.sam.gov/portal/public/SAM/. ix. FAR clause 52.212-4, Contract Terms and Conditions - Commercial Items applies to this Acquisition. x. FAR clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items applies to this Acquisition. xi. The Defense Priorities and Allocations System (DPAS) and assigned rating does not apply to this acquisition. Offerors shall submit their proposals no later than 7:30 a.m. Eastern Standard Time (EST) on August 14, 2013. The proposal must reference the RFP Number: NHLBI-CSB-(HG)-2013-237-DLM. All responsible offerors may submit a proposal, which if timely received, shall be considered by the agency. Proposals can be emailed to the Contracting Specialist, Dorothy Maxwell at maxwelld@nhlbi.nih.gov; Quotations shall not be deemed received by the Government until the quotation is entered into the e-mail address inbox set forth above. Faxed proposals will NOT be accepted. Offerors' proposals shall not be deemed received by the Government until the proposal is entered into the e-mail address inbox set forth above. All quotes shall contain the following: 1. Name of Contracting Organization; 2. Contract Number (for subcontracts, provide the prime contract number and the subcontract number); 3. Contract Type; 4. Total Contract Value and Discounts; 5. Description of Requirement; 6. Contracting Officer's Name and Telephone Number; 7. North American Industry Classification System (NAICS) Code; and 8. DUNS Number. Offerors must complete annual representations and certifications on-line at https://www.sam.gov/portal/public/SAM/.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(HG)-2013-237-DLM/listing.html)
- Place of Performance
- Address: NIH, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03140995-W 20130809/130808000327-52f60458073466cab4c2427db733c80d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |